BioNTech Announces Positive Topline Phase 2 Results for mRNA ...
WEBJul 30, 2024 · The randomized trial evaluates the clinical activity and safety of the investigational mRNA cancer immunotherapy BNT111 in combination with Libtayo ® (cemiplimab), an anti-PD-1 monoclonal antibody being developed by Regeneron, and assesses the two single agents alone.
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety ...
WEBApr 1, 2021 · Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and ...
Newsroom - BioNTech
WEBVideos, photos, press releases or data sheets Learn more about BioNTech!
Pfizer and BioNTech Announce Positive Topline Data for mRNA …
WEBOct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
WEBDec 11, 2020 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY ® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
US FDA authorizes Pfizer-BioNTech and Moderna's updated …
WEBSept 11 (Reuters) - The U.S. Food and Drug Administration (FDA) on Monday authorized updated COVID-19 vaccines from Pfizer (PFE.N) /BioNTech (22UAy.DE) and Moderna (MRNA.O) that target a recently...
BioNTech is proceeding with COVID-shot in line with WHO …
WEBFRANKFURT, May 25 (Reuters) - Germany's BioNTech (22UAy.DE) said it was on track to introduce a COVID-19 shot by the early fall in the northern hemisphere that is adapted to currently dominant...
BioNTech’s Founders on A.I. and the Future of Cancer Treatment
WEBDec 5, 2023 · Dr. Ugur Sahin and Dr. Özlem Türeci are pioneers in the field of mRNA vaccines and personalized cancer immunotherapies, and are the scientific founders of BioNTech.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
WEBDec 10, 2020 · Here, we report safety and efficacy findings from the phase 2/3 part of a global phase 1/2/3 trial evaluating the safety, immunogenicity, and efficacy of 30 μg of BNT162b2 in preventing Covid-19 in...
BioNTech SE (BNTX) Latest Stock News & Headlines - Yahoo …
WEBGet the latest BioNTech SE (BNTX) stock news and headlines to help you in your trading and investing decisions.